Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 48

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 48
---
 period of one year from the date these unaudited condensed financial statements are issued.

Management is actively pursuing additional sources of funding through equity
and debt financing to support the Company’s operating plan. Although Milestone Scientific has successfully raised capital in the
past, there can be no assurance that additional financing will be available on acceptable terms, or at all. The terms of any such financing
may adversely affect the rights or holdings of existing stockholders.

The Company continues to focus on generating positive cash flow from operations
by increasing revenue from its dental business worldwide, expanding sales of its medical devices and disposables in the United States
and abroad, and reducing operating expenses. However, the continuation of operations is dependent upon the Company’s ability to
raise additional capital and ultimately achieve sustained profitability.

 25 

Item
3. Quantitative and Qualitative Disclosures about Market Risk

Milestone
Scientific is a “smaller reporting company” as defined by Regulation S-K and, as such, is not required to provide the information
required by this item.

Item
4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and
Principal Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2025. The term
“disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), refers to controls and other procedures designed to ensure that information required to be
disclosed by a company in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the
time periods specified in the SEC’s rules and forms.

Disclosure controls and procedures include, without limitation, controls
and procedures designed to ensure that information required to be disclosed by a company is accumulated and communicated to management,
including the principal executive and principal financial officers (or persons performing similar functions), as appropriate, to allow
timely decisions regarding required disclosure.

Management recognizes that any system of controls and procedures, no matter
how well designed and operated, can provide only reasonable assurance of achieving its objectives. Accordingly, management must apply
judgment in evaluating the cost-benefit relationship of potential control enhancements. Based on their evaluation, our Chief Executive
Officer and Principal Accounting Officer concluded that, as of September 30, 2025, our disclosure controls and procedures were effective
at a reasonable